What Простамол Уно Treats: Main Uses and Benefits

Простамол Уно is generally used to provide symptomatic relief in men dealing with mild-to-moderate Lower Urinary Tract Symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The herbal extract is indicated to help relieve the urologic symptoms associated with this condition. This places the treatment within the domain of conservative management, where it is applicable within clinical settings that involve acute or disruptive symptom patterns. The treatment supports the patient by generally providing anti-oedematous and anti-inflammatory benefits to the prostate tissue.

Symptom Clusters Addressed

This medication is relevant for easing symptoms related to heightened physiological activity, specifically targeting irritative urinary symptoms (storage issues) and nocturia (waking up at night to urinate). This symptomatic relief contributes to easing the overall symptom load, which may help patients cope more steadily with symptom fluctuations. The medication is also relevant for easing symptom clusters that may become intense or disruptive, such as urinary hesitancy (difficulty starting the stream), a weak or slow urine flow, and the sensation of incomplete bladder emptying.

“The treatment may be part of symptomatic management for the frequent urge to urinate, a factor which often disrupts sleep and general comfort.”

By assisting with managing these issues, the treatment contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Who Can and Cannot Use Простамол Уно?

This section describes the population eligibility rules for Простамол Уно (Serenoa repens Fructuum Extract) as defined by official regulatory documentation. The use of this medicine is strictly defined by the intended male-specific indication, Benign Prostatic Hyperplasia (BPH).

---

Official Eligibility and Contraindications

Category	Eligibility Status (Regulatory)
Eligible Target Population	Adult men (18 years) seeking symptomatic relief of LUTS associated with BPH.
Absolute Contraindications	Patients with known hypersensitivity to the active substance or any excipient. Women (including during pregnancy and lactation).
Age-Related Restrictions	Not Recommended for use in children and adolescents under 18 years of age.

The regulatory profile dictates strict boundaries for use. The medicine is contraindicated in the female population due to the gender-specific indication and lack of safety data. Similarly, it is not recommended for children and adolescents because safety and efficacy have not been established in these age groups. Unless contraindicated, use is established for adult men.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Простамол Уно (Serenoa repens Fructuum Extract) around potential pharmacodynamic risks, while generally noting a low risk for metabolic interference.

Category	Official Regulatory Statement
Interacting medicinal product categories	Anticoagulant and Antiplatelet Drugs; Estrogens and Hormonal Contraceptives.
Mechanistic basis of interactions	Pharmacodynamic effect: Potential for an additive effect on blood coagulation. Pharmacodynamic (Theoretical): Potential to interfere with hormonal balance.
Timing-based interaction rules	None are officially documented; no mandatory time separation is required.
Population-specific interaction notes	Caution applies to patients scheduled for surgery (pre-procedural restriction).
Interaction-related restrictions	Discontinuation is recommended prior to scheduled surgical procedures due to the possibility of affecting blood coagulation.

Official Interaction Statements

• The product has been associated with a few suspected cases of interaction with anticoagulant drugs, suggesting a potential additive effect on blood coagulation and a risk for increased International Normalized Ratio (INR) values.
• A theoretical risk exists for decreased efficacy when co-administered with estrogens or oral contraceptives, based on the presumed anti-estrogenic properties of the extract's components.
• Regulatory cautions advise for the discontinuation of use before surgery to mitigate the potential to affect normal blood clotting processes.
• Regulatory reviews generally classify the extract as having a low potential for pharmacokinetic interactions, with no specific inhibition or induction of major drug-metabolizing enzymes (CYP or transporters) formally established in regulatory labeling.

Connection to the overall interaction profile

Regulatory documentation defines the product's interaction structure predominantly by its potential for pharmacodynamic interference, specifically impacting blood coagulation and, theoretically, hormonal balance. This profile mandates procedural cautions like pre-surgical discontinuation but is defined by the absence of formally documented clinically significant metabolic or transporter-based pharmacokinetic interactions with conventional medicines.

The mechanistic action is driven by a multi-modal pharmacological profile that collectively engages the hormonal, muscular, and inflammatory pathways critical to the underlying prostatic condition. The extract's various components collectively engage these different mechanistic domains.

Dual Modulation of Androgen Signaling

This domain addresses the androgen-mediated cellular proliferation pathway by targeting the 5alpha-reductase enzyme and the Androgen Receptor . The active phytosterols in the extract inhibit the enzyme that converts Testosterone to Dihydrotestosterone (DHT), and also block DHT's binding to its intracellular receptor. This sequential action locally modulates the primary trophic signal for prostatic cells, contributing to the modulation of cellular proliferation signaling.

Modulation of Prostatic Smooth Muscle Tone

The extract engages mechanisms that modulate the smooth muscle tone of the prostate by acting as a functional antagonist at the alpha1-Adrenergic Receptors located in the prostatic stroma and the bladder neck. By interfering with sympathetic signaling, this action directly modulates the tissue tone, which in turn influences the diameter of the urethral lumen and contributes to the modulation of fluid passage dynamics.

️ Modulation of Local Prostatic Inflammation

This mechanism focuses on modulating the inflammatory cascade by inhibiting key enzymes like Cyclooxygenase (COX) and Lipoxygenase (LOX), alongside the modulation of local pro-inflammatory mediators. By limiting the production of these mediators, the drug is associated with a reduction of localized fluid accumulation and vascular congestion within the prostate gland.

How to use Простамол Уно: Official Administration Guidelines

The usage of Простамол Уно (Serenoa repens 320 mg soft capsules) is governed by specific instructions, which dictate the necessary administration route, dose, and timing. This phytotherapeutic agent is approved exclusively for oral use.

Administration Protocol

The established regimen for adults and older men is to take one soft capsule per day, corresponding to a daily dose of 320 mg of the standardized extract. Standard administration guidelines specify that the capsule must be taken after a meal (with food) and should be swallowed whole with liquid; the capsule must not be chewed. Consistent daily administration, preferably at the same time each day, is required for the treatment.

Duration of Use and Population Rules

Official documents define the target user group as adults and older people (men aged 18 and over); there is no sanctioned use for women or individuals under 18 years of age. While the duration of therapy is not formally limited, guidelines suggest a minimum treatment course of not less than three months. This minimum period is established to allow for consistent administration before assessment. The prescribed daily dose must not be exceeded, and regular use is essential to the overall use protocol.

Research evidence / Overview of Studies for Простамол Уно

Evidence for Symptomatic Relief of Lower Urinary Tract Symptoms (LUTS)

Research has been conducted on the specific extract in Простамол Уно, involving men experiencing bothersome Lower Urinary Tract Symptoms (LUTS) associated with mild-to-moderate Benign Prostatic Hyperplasia (BPH). Studies focused on outcomes reflecting daily functioning, such as the overall severity of urinary symptoms (IPSS) and patient-reported quality of life. Findings describe measured patterns related to these symptom scores during the study period.

Trial Design and Measured Outcomes

The research base includes Randomized Controlled Trials (RCTs) where the extract was studied alongside both placebo and established prescription medications for BPH. Within these research scenarios, functional measures were consistently monitored, including maximum urinary flow rate (Qmax), post-void residual volume, and nocturia frequency.

---

Comparative Studies Against Placebo and Prescription Medicines

Some placebo-controlled trials have been conducted to study the extract’s impact on symptom severity relative to an inert pill. Findings across all research exploring Serenoa repens extracts against placebo were mixed and sometimes inconsistent. When evaluated against active prescription drugs, data show patterns related to non-inferiority in measured outcomes in certain specific trials, but the findings were not uniform across all published systematic analyses.

---

Long-Term Studies and Durability of Follow-up

The research base includes studies that monitored patient responses up to 12 to 24 months. However, comprehensive long-term evidence remains limited in the body of large-scale, long-duration RCTs. While some observational studies describe patterns related to sustained measurements over two years, there is limited information for long-term outcomes in certain key areas.

---

Research in Specific Patient Groups

The majority of published research was evaluated in adult and elderly men with mild-to-moderate LUTS. Data for certain groups remain insufficient or limited. For example, there is limited information on how the specific extract was observed in populations with severe BPH symptoms or complex medical conditions (comorbidities).

---

What Research Shows About Evidence Quality and Uncertainty

The body of research on Serenoa repens is structured around multiple clinical trials and regulatory classifications, such as "well-established medical use" by some bodies, though certainty remains a factor. Evidence quality varies across studies due to differing extracts. Follow-up durations were limited in many early studies, and the full extent of long-term outcomes is an area where certainty remains low. The evidence highlights what is known—and what is still uncertain—about this phytotherapeutic agent.

Key Studies & References Efficacy and safety of Hexanic extract of Serenoa Repens (Permixon) versus Finasteride in men with moderate LUTS secondary to BPH: a randomized, controlled trial

Common questions about Простамол Уно (FAQ)

---

Q: What should I do if I forget to take my daily dose?

Specific instructions for managing a forgotten dose are generally not detailed in the official product information. Consistent with standard regulatory guidance for this type of medication, official documentation advises against taking a double dose to compensate for a missed dose.

---

Q: Can Простамол Уно be taken by people with diabetes?

Official product information for this herbal medicine does not typically list diabetes as a direct contraindication. However, the use of herbal supplements by individuals with existing medical conditions is best discussed with a healthcare provider before starting any new treatment.

---

Q: Will Простамол Уно affect PSA test results?

Official regulatory labels may advise that regular medical checks, including monitoring by way of a PSA test, should continue during treatment, as the medicine is for symptomatic relief only. The available regulatory information does not specifically describe direct interference with the PSA test.

---

Q: Is alcohol consumption restricted while using Простамол Уно?

Official product information typically does not list a specific contraindication or warning against the consumption of alcohol. However, general information about BPH management notes that excessive alcohol consumption may worsen urinary symptoms, which is a consideration for patients.

---

Q: How quickly do people typically start to notice any effects from Простамол Уно?

The onset of symptomatic relief with this medicine is often described as gradual, reflecting the nature of the condition it addresses. Regulatory guidance suggests maintaining consistent administration for a minimum duration, such as at least three months, before the therapeutic effect is fully assessed.

---

Q: Does Простамол Уно have any contraindications listed for liver or kidney problems?

The official product contraindications usually only list hypersensitivity to the active substance and its use in women or children. Specific warnings for severe liver or kidney impairment may be listed in the precautions section, which highlights the need for a healthcare provider to assess its appropriateness in these cases.

---

Q: Are there any specific lifestyle changes recommended alongside taking Простамол Уно?

Official regulatory documents focus only on the medicine itself and its usage. However, general BPH management information often discusses lifestyle approaches. Examples of general BPH management approaches often mentioned include limiting nighttime fluid intake or avoiding certain substances that may act as bladder irritants.

---

Q: How does the active ingredient in Простамол Уно get absorbed?

The active substance, a lipidosterolic extract, is absorbed within the gastrointestinal tract following oral intake. Regulatory information on the medicine’s absorption (pharmacokinetics) indicates that its fat-soluble nature influences how the body takes up the active components.

---

Q: Is a doctor's consultation mandatory before starting Простамол Уно?

Regulatory documents state that use is intended to be for patients with a confirmed diagnosis of BPH, even if the medicine is available over-the-counter. Official warnings also advise seeking medical attention immediately if symptoms worsen, new symptoms appear, or if blood is observed in the urine.

---

Q: Can Простамол Уно affect libido or sexual function?

Some official reviews of the active ingredient have reported a rare risk of decreased libido or sexual dysfunction. These reports are included in the safety information that accompanies the product.

---

Q: What should I look for to know if Простамол Уно is working?

Expected symptomatic goals described in regulatory documents include improvements in urinary flow and a reduction in the frequency of urination, particularly nocturia (nighttime urination). The medicine is intended to provide symptomatic relief for Lower Urinary Tract Symptoms (LUTS) related to BPH.

---

Q: Are there any warnings for drivers or machinery operators listed for Простамол Уно?

Based on the safety profile and the nature of the documented side effects, the official product information states that Простамол Уно is expected to have no influence or only a negligible influence on a person’s ability to drive vehicles or operate heavy machinery.

---

Q: Do people report trouble sleeping after starting Простамол Уно?

Official adverse reaction reports do not commonly list insomnia or trouble sleeping as a documented side effect of the medicine. Sleep disturbances are typically associated with the underlying condition, nocturia, for which the medicine provides symptomatic management.

---

Q: Is there a public registry where I can find official patient leaflets for Простамол Уно?

Official patient information leaflets (PILs) and Summaries of Product Characteristics (SmPCs) are publicly available. These documents can be accessed on the websites of the national regulatory authorities in the countries where the medicine has received approval.

---

Q: What are the signs of an overdose of Простамол Уно?

Specific guidance on the clinical signs of an overdose may not be detailed in the regulatory label due to the extract's low toxicity profile. In the event of a suspected overdose, the official guidance is that seeking immediate medical attention from a healthcare provider or hospital is necessary for monitoring.

How to Store and Dispose of Prostamol Uno

Official regulatory documentation establishes specific requirements for the storage and disposal of Prostamol Uno soft capsules.

Storage Conditions

Prostamol Uno must be stored at a temperature of not more than 25°C. This temperature constraint is necessary to maintain the integrity of the soft capsules and the product's 3-year shelf-life until the labeled expiration date. For child safety, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

To comply with environmental regulations, unused or expired Prostamol Uno should not be discarded into the sanitary sewage system or household waste containers. Official instructions direct users to ask the pharmacist what to do with the drugs they do not need to ensure proper disposal as pharmaceutical waste.